regulated by a network of proteins such as ATM or Chk2 and their activated forms (phosphorylated).
INTRODUCTION AND OBJECTIVES:
Recent studies have reported that centrosome amplification (CA) is closely related to chromosomal instability (CIN) and patient prognosis in human malignancies. The relationship between DNA copy number aberrations (DCNAs) and CA remains to be elucidated. Therefore we examined the relationship between CA and genomic alterations in urothelial carcinomas. To our knowledge, this is the first report to confirm CA as a reliable biomarker for assessing DCNAs in urothelial carcinomas.
METHODS: Centrosomes were evaluated by immunohistochemistry using an anti-g-tubulin antibody. Array-based comparative genomic hybridization technology using DNA chips was applied to 70 urothelial carcinomas to examine DCNAs in the entire genome. Studying aberrations in the number of chromosomes 7, 9 and 17 using fluorescence in situ hybridization allowed for the estimation of the degree of CIN. We compared DCNAs and CIN with CA and tumor grade. Further, the patient prognosis of these parameters was evaluated.
RESULTS: DNA copy number gains at 20p12.2, 5p15.2, 5p15.31, and 17q25.3 and losses at 17p12, 8p22, 2q37.3, 5q31.1, and 2q37.3 were more frequent in tumors with CA than in those without it. The total numbers of DCNAs and frequency of CIN were also larger in tumors with CA than in those without it (P ¼ 0.0263 and P < 0.0001, respectively). These parameters were more closely associated with CA than with subjectively assigned tumor grade (Table) . Recurrence-free survival rate was higher in tumors without CA than in those with it (P ¼ 0.0307) but was not statistically different between high and low grade tumors (P ¼ 0.5529). For the subgroup of patients with low grade tumors, CIN and tumor recurrence were more frequent in tumors with CA than in those without it (P ¼ 0.0111 and P ¼ 0.0242, respectively).
CONCLUSIONS: These data suggest that CA may have great potential as a biomarker for improved objective classification of urothelial carcinoma and estimation of prognosis. Tumors with CA have large total numbers of DCNAs and CIN, and therefore, these tumors may have worse prognoses. 
Source of

INTRODUCTION AND OBJECTIVES:
A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18), located on 16p23.1, is involved in carcinogenesis of multiple cancers, but its role in bladder cancer (BCa) remains unclear. Here, we reported the epigenetic alterations of ADAMTS18 and its function in bladder carcinogenesis.
METHODS: We detected ADAMTS expression in normal BCa tissue, BCa cell lines and primary tumors by semi-quantitative RT-PCR and immunohistochemistry, and further assessed its tumor suppressive functions. Methylation-specific PCR and bisulfite genomic sequencing were used to examine the methylation status of ADAMTS18 in nonmuscle invasive/muscle invasive bladder cancer tissues and urine sediments.
RESULTS: We found that ADAMTS18 was highly expressed in normal bladder cell line and tissue, but frequently downregulated in BCa cell lines and tissues. Moreover, pharmacologic demethylationcould restore ADAMTS18 expression. We further detected ADAMTS18 methylation in our clinical specimens, and found that ADAMTS18 was methylated in 14/17 muscle invasive tumors primary tumors, but relatively lower in non-muscle invasive tissues (13/30). ADAMTS18 methylation was also associated with high pathologic grade (p¼0.017). Then the tumor suppressor function of ADAMTS18 was detected in T24. Ectopic expression of T24 inhibited the colony formation and suppressed migration of bladder caner cells.
CONCLUSIONS: Taken together, our data suggests that ADAMTS18 as a functional tumor suppressor is frequently methylated in BCa and associates with tumor stage and grade, indicating that it may serve as a tumor prognosis marker for BCa diagnosis.
Source of Funding: none
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